3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

This invention relates generally to methods and compositions for the treatment or prevention of critical illness myopathy and critical illness polyneuropathy and of critical illness myopathy and critical illness polyneuropathy caused by critical illnesses including sepsis, severe sepsis, severe sepsis with septic shock, and particularly to the use of a combination of parenteral or enteral feeding with a 3-hydroxybutyrate.

Octrooi-publicatienummer: EP3558291

Jaar aanvraag: 2017

Jaar toekenning: 2020

Jaar van publicatie: 2019

Status: Aangevraagd

Technologiedomeinen: Farmaceutische producten

Gevalideerd voor IOF-sleutel: Ja

Toegewezen aan: Associatie KULeuven